InsiderTrades.com logo
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Michael Wayne Kalb net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michael Kalb Biography and Net Worth

CFO of Amarin
Michael Wayne Kalb serves as Chief Financial Officer, Senior Vice President, Assistant Secretary of the Company. Mr. Kalb served as Group Vice President, Chief Financial Officer and Chief Accounting Officer of Taro Pharmaceutical Industries Ltd. from August 2014 to June 2016. Prior to that, Mr. Kalb was GVP, Interim CFO and CAO from November 2010 to August 2014 and GVP, Chief Financial Officer—U.S. and CAO from May 2010 to November 2010. Mr. Kalb joined Taro in June 2009 as VP, Chief Financial Officer—U.S. He has over 20 years of financial and accounting advisory experience. From June 2004 to June 2009, Mr. Kalb served as a Director in the Accounting and Financial Consulting Group of Huron Consulting Group Inc. His experience also includes over ten years at Ernst & Young, LLP within the Transaction Advisory Services Group and Audit and Assurance Services Group. Mr. Kalb received a B.S. in Accounting from the University at Albany, State University of New York. Mr. Kalb is a Certified Public Accountant.

How do I contact Michael Wayne Kalb?

The corporate mailing address for Mr. Kalb and other Amarin executives is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. Amarin can also be reached via phone at (531) 669-9020 and via email at [email protected]. Learn More on Michael Wayne Kalb's contact information.

Has Michael Wayne Kalb been buying or selling shares of Amarin?

Michael Wayne Kalb has not been actively trading shares of Amarin in the last ninety days. Most recently, Michael Wayne Kalb sold 120,000 shares of the business's stock in a transaction on Thursday, August 12th. The shares were sold at an average price of $5.25, for a transaction totalling $630,000.00. Learn More on Michael Wayne Kalb's trading history.

Who are Amarin's active insiders?

Amarin's insider roster includes Michael Kalb (CFO), Joseph Kennedy (General Counsel), Steven Ketchum (Insider), David Stack (Director), and Joseph Zakrzewski (Director). Learn More on Amarin's active insiders.

Are insiders buying or selling shares of Amarin?

During the last twelve months, Amarin insiders bought shares 2 times. They purchased a total of 174,426 shares worth more than $118,124.34. During the last twelve months, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 34,131 shares worth more than $26,963.49. The most recent insider tranaction occured on August, 2nd when CEO Aaron Berg bought 160,000 shares worth more than $102,400.00. Insiders at Amarin own 2.0% of the company. Learn More about insider trades at Amarin.

Information on this page was last updated on 8/2/2024.

Michael Wayne Kalb Insider Trading History at Amarin

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2021Sell120,000$5.25$630,000.00View SEC Filing Icon  
7/1/2019Sell50,000$19.67$983,500.00View SEC Filing Icon  
3/1/2019Sell100,000$22.09$2,209,000.00View SEC Filing Icon  
2/22/2019Sell50,000$18.97$948,500.00View SEC Filing Icon  
2/15/2019Sell25,000$17.58$439,500.00View SEC Filing Icon  
1/9/2019Sell200,000$15.26$3,052,000.00View SEC Filing Icon  
9/24/2018Sell150,000$10.42$1,563,000.00View SEC Filing Icon  
See Full Table

Michael Wayne Kalb Buying and Selling Activity at Amarin

This chart shows Michael Wayne Kalb's buying and selling at Amarin by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amarin Company Overview

Amarin logo
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $0.50
Low: $0.50
High: $0.52

50 Day Range

MA: $0.59
Low: $0.50
High: $0.63

2 Week Range

Now: $0.50
Low: $0.50
High: $1.37

Volume

2,005,382 shs

Average Volume

1,531,844 shs

Market Capitalization

$205.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.